| Derek Joseph Davenport, MD | |
|
4095 E Pony Express Pkwy Ste 1, Eagle Mountain, UT 84005-5531 | |
| (801) 429-8037 | |
| (801) 753-7476 |
| Full Name | Derek Joseph Davenport |
|---|---|
| Gender | Male |
| Speciality | Pediatric Medicine |
| Experience | 15 Years |
| Location | 4095 E Pony Express Pkwy Ste 1, Eagle Mountain, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346484581 | NPI | - | NPPES |
| 1346484581 | Other | NPI | |
| 500659989 | Medicaid | OR |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Utah Clinic Pc | 7517868508 | 391 |
News Archive
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and six months ended June 30, 2011.
Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., today announced that IPX066 APEX-PD Phase III clinical study data will be presented in a Late Breaker Session at the 63rd annual meeting of the American Academy of Neurology Conference in Honolulu, Hawaii, held from April 9 to April 16.
Teva Pharmaceutical Industries, Ltd. announced today that Copaxone® (glatiramer acetate injection), has now achieved one million patient years of experience in the treatment of relapsing-remitting multiple sclerosis (RRMS). This analysis is based on internal data submitted annually to the U.S. Food and Drug Administration (FDA).
Many health problems in the developed world stem from the disruption of a delicate metabolic balance between glucose production and energy utilization in the liver.
Early in the COVID-19 pandemic, Mount Sinai researchers were among the first to show that anticoagulation therapy was associated with improved survival among hospitalized COVID-19 patients
› Verified 3 days ago
| Entity Name | Central Utah Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093764805 PECOS PAC ID: 7517868508 Enrollment ID: O20040113000805 |
News Archive
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and six months ended June 30, 2011.
Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., today announced that IPX066 APEX-PD Phase III clinical study data will be presented in a Late Breaker Session at the 63rd annual meeting of the American Academy of Neurology Conference in Honolulu, Hawaii, held from April 9 to April 16.
Teva Pharmaceutical Industries, Ltd. announced today that Copaxone® (glatiramer acetate injection), has now achieved one million patient years of experience in the treatment of relapsing-remitting multiple sclerosis (RRMS). This analysis is based on internal data submitted annually to the U.S. Food and Drug Administration (FDA).
Many health problems in the developed world stem from the disruption of a delicate metabolic balance between glucose production and energy utilization in the liver.
Early in the COVID-19 pandemic, Mount Sinai researchers were among the first to show that anticoagulation therapy was associated with improved survival among hospitalized COVID-19 patients
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Derek Joseph Davenport, MD 1055 N 500 W, Attn. Credentialing, Provo, UT 84604 Ph: (801) 354-8225 | Derek Joseph Davenport, MD 4095 E Pony Express Pkwy Ste 1, Eagle Mountain, UT 84005-5531 Ph: (801) 429-8037 |
News Archive
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and six months ended June 30, 2011.
Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., today announced that IPX066 APEX-PD Phase III clinical study data will be presented in a Late Breaker Session at the 63rd annual meeting of the American Academy of Neurology Conference in Honolulu, Hawaii, held from April 9 to April 16.
Teva Pharmaceutical Industries, Ltd. announced today that Copaxone® (glatiramer acetate injection), has now achieved one million patient years of experience in the treatment of relapsing-remitting multiple sclerosis (RRMS). This analysis is based on internal data submitted annually to the U.S. Food and Drug Administration (FDA).
Many health problems in the developed world stem from the disruption of a delicate metabolic balance between glucose production and energy utilization in the liver.
Early in the COVID-19 pandemic, Mount Sinai researchers were among the first to show that anticoagulation therapy was associated with improved survival among hospitalized COVID-19 patients
› Verified 3 days ago